Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)
Latest Information Update: 02 Nov 2022
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Brain metastases; Renal cell carcinoma
- Focus Adverse reactions
- Acronyms CHECKMATE 920
- Sponsors Bristol-Myers Squibb
- 25 Apr 2022 Status changed from active, no longer recruiting to completed.
- 16 Nov 2021 Results assessing safety and efficacy of NIVO + IPI in a cohort that included patients with aRCC and brain metastases published in the Cancer
- 08 Jun 2021 Updated Results (n=28) evalauting safety and efficacy results for the cohort of patients with aRCC of any histology and brain metastases, presented at the 57th Annual Meeting of the American Society of Clinical Oncology